Common Symptoms of Bird Flu in Humans
Human infections with avian influenza viruses, primarily H5N1 and H7N9, often begin with high fever, cough, sore throat, and muscle aches, closely resembling seasonal flu. Patients may also experience headache, fatigue, and respiratory distress early in the illness. The World Health Organization tracks these presentations as key indicators for suspected cases. For detailed clinical updates, see the WHO influenza overview.
Severe cases can rapidly progress to pneumonia, acute respiratory distress syndrome, and multi-organ failure. Gastrointestinal symptoms such as nausea, vomiting, and diarrhea have also been reported. Neurological changes, including encephalitis, are rare but documented. Early recognition is critical because the case fatality rate for H5N1 has historically exceeded 50 percent in reported human instances, according to the CDC bird flu symptoms page.
Transmission, Risk Factors, and Current Outbreak Context
Human infections occur mainly through direct contact with infected poultry or contaminated environments, with sustained human-to-human transmission remaining rare. Workers in poultry farms, live bird markets, and veterinary services face elevated exposure risk. The U.S. Centers for Disease Control and Prevention issues regular risk assessments for circulating avian strains. The CDC risk assessment reports outline current exposure levels.
The ongoing global H5N1 clade 2.3.4.4b has spread among wild birds and dairy cattle in multiple regions since 2024, prompting heightened surveillance. As of mid-2025, sporadic human cases have been reported in several countries, with the majority linked to poultry exposure. The Food and Agriculture Organization monitors avian influenza in livestock and wildlife. For outbreak data, refer to the FAO animal influenza portal.
Diagnosis, Treatment, and Public Health Response
Laboratory confirmation requires real-time reverse transcription polymerase chain reaction testing on respiratory specimens, with viral sequencing identifying the specific avian subtype. Antiviral treatment with oseltamivir is recommended early in the course of illness, ideally within 48 hours of symptom onset. Corticosteroids are generally avoided unless indicated for other critical conditions. The FDA has issued emergency use authorizations for certain diagnostic assays during outbreaks.
Public health agencies activate surveillance and contact tracing when human cases are confirmed, and candidate vaccine viruses are updated annually to match circulating strains. The Biomedical Advanced Research and Development Authority supports the development of avian influenza medical countermeasures. Vaccine effectiveness data for current H5 candidate vaccine viruses are available through peer-reviewed publications and agency briefings. For regulatory and clinical trial information, see the FDA influenza vaccines page.